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Abstract: Limited studies have shown that Coleus forskohlii extract may aid in weight
management. This randomized, double blind placebo-controlled clinical study assessed the effects
of supplementation with C. forskohlii extract on key markers of obesity and metabolic parameters in
overweight and obese individuals. Thirty participants completed the trial and they were randomly
assigned to receive either 250 mg of C. forskohlii extract (n = 15) or a placebo twice daily for 12 weeks.
All participants were advised to follow a hypocaloric diet throughout the study. Body weight,
body mass index (BMI), waist and hip circumference, and waist to hip ratio, were monitored
fortnightly. Dietary intake was assessed at the baseline and weeks 4, 8 and 12. Appetite was assessed
using visual analogue scales and blood samples were analyzed for plasma lipids, ghrelin, leptin,
glucose and insulin at the baseline and end of the intervention. Significant reductions to waist
and hip circumference (p = 0.02; p = 0.01, respectively) were recorded in both experimental and
placebo groups after the 12 week intervention. Furthermore, high density lipoprotein-cholesterol
(HDL-C) was significantly increased (p = 0.01) in both groups. The experimental group showed a
favorable improvement in insulin concentration and insulin resistance (p = 0.001; 0.01 respectively)
compared to the placebo group. These findings suggest that C. forskohlii extract in conjunction with
a hypocaloric diet may be useful in the management of metabolic risk factors.
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1. Introduction
Metabolic syndrome is a common cardio-metabolic disorder that is characterized by the
simultaneous occurrence of cardiovascular risk factors including central obesity, dyslipidemia,
hyperglycemia and hypertension [1]. Central obesity is a major predisposing factor to the
development of metabolic syndrome and is a key component of metabolic syndrome [2–4]. The
exact mechanism by which metabolic syndrome develops is not yet fully understood but it appears
to be related to insulin resistance and excessive free fatty acid release from intra-abdominal
adipocytes [5–7]. It is also believed that a pro-inflammatory and pro-thrombotic state contribute to the
pathogenesis of the syndrome [8]. Metabolic syndrome poses a major health risk for the development
of cardiovascular disease (CVD) and type II diabetes mellitus (T2DM), thus an effective therapeutic
approach is in high demand for those who are at risk [9]. The majority of individuals affected with
metabolic syndrome are overweight or obese and therefore treatment is primarily focused on weight
reduction [10–12].
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Lifestyle interventions such as dietary modification and physical activity remain the cornerstone
of weight loss treatment. In theory, reducing energy intake and increasing energy expenditure
will elicit weight loss [10]. However, obesity is a multifactorial condition encompassing complex
environmental and genetic influences leading to overconsumption and reduced physical activity
making weight loss a challenging issue [13]. As the prevalence of overweight and obesity continues
to rise at an alarming rate, more effective weight-control therapies are required [14]. The availability
and popularity of natural weight loss supplements has increased drastically over recent years. Coleus
forskohlii auct. (Plectranthus barbatus Andrews) extract is among those natural products that shows
promising therapeutic anti-obesity potential [15].
Coleus forskohlii auct. is a perennial plant of the Lamiaceae (mint) family and is native to Nepal,
Thailand and India. Forskolin is the major active constituent of C. forskohlii which is of clinical
interest [16]. Forskolin (7β-Acetoxy-8, 13-epoxy-1α, 6β, 9α-trihydroxy-labd-14-ene-11-one) (Figure 1)
is a labdane diterpene that was first isolated from the plant in 1974. Forskolin is extracted from the
tuberous roots of the plant and thus far, C. forskohlii is the only species known to contain significant
amounts of the bioactive component [17]. It has been documented that forskolin increases the rate
of lipolysis via cyclic adenosine monophosphate (cAMP) accumulation by mechanisms independent
of hormonal stimulation both in vitro [18,19] and in animal models [20,21]. Furthermore, forskolin
also directly activates hormone sensitive lipase by phosphorylation of protein kinase A resulting in
further lipolysis and release of free fatty acids [19].
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Figure 1. Chemical structure of forskolin. 
Limited human studies have indicated that supplementation with C. forskohlii extract elicits 
favorable changes to body composition. Godard, et al. [22] found a significant reduction of body fat 
percentage in overweight and obese men after 12 weeks of supplementation with C. forskohlii extract. 
Similar results have also been documented in preliminary open-label trials conducted on overweight 
and obese female volunteers [23] and men and women within the healthy BMI range (24.92 ± 0.87) [24]. 
In addition, Henderson, et al. [25] reported significant reductions in dietary intake in overweight 
women but did not find any significant differences in subjective appetite sensations or body composition 
after 12-weeks of supplementation. The aim of the present study was to evaluate the effects of 12-weeks 
supplementation with C. forskohlii extract on dietary intake and appetite, anthropometric measures, and 
metabolic parameters in overweight and obese individuals. To the best of our knowledge, this is the 
first study investigating the efficacy of C. forskohlii extract on the appetite hormones, leptin and 
ghrelin, and insulin sensitivity in overweight and obese individuals. 
2. Experimental Section 
2.1. Participants and Randomization 
This study was a double blind, placebo-controlled randomized clinical trial conducted at Victoria 
University, Melbourne, Australia. Participants were recruited through the general community, staff 
members and students from May to July 2014. Forty-one overweight or obese participants (12 males 
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Figure 1. Chemical structure of forskolin.
Limited human studies have indicated that supplementation with C. forskohlii extract elicits
favorable changes to body composition. Godard, et al. [22] found significant eduction of body
fat percentage in overweight and obese men after 12 weeks of supplementation with C. forskohlii
extract. Similar results have also been documented in preliminary open-label trials conducted on
overweight and obese female volunteers [23] and men and women within the healthy BMI range
(24.92 ˘ 0.87) [24]. In addition, Henderson, et al. [25] reported significant reductions in dietary intake
in overweight women but did not find any significant differences in subjective appetite sensations or
body composition after 12-weeks of supplementation. The aim of the present study was to evaluate
the effects of 12-weeks supplementation with C. forskohlii extract on dietary intake and appetite,
anthropometric measures, and metabolic parameters in overweight and obese individuals. To the
best of our knowledge, this is the first study investigating the efficacy of C. forskohlii extract on the
appetite hormones, leptin and ghrelin, and insulin sensitivity in overweight and obese individuals.
2. Experimental Section
2.1. Participants and Randomization
This study was a double blind, placebo-controlled randomized clinical trial conducted at Victoria
University, Melbourne, Australia. Participants were recruited through the general community,
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staff members and students from May to July 2014. Forty-one overweight or obese participants
(12 males and 29 females) were enrolled in the trial (Figure 2). All participants were screened
to assess eligibility prior to enrolling and informed written consent was obtained. The eligibility
criteria included: BMI > 25 m² or waist circumference > 94 cm (male) and > 80 cm (female),
20–65 years, non-smoker, non-pregnant or lactating, non-type 1 diabetic, no present liver, kidney
or heart disease, not susceptible to peptic ulcers and not taking any medication for weight loss,
hypertension or thrombocytosis. Prior to randomization, an initial assessment was conducted to
measure participant’s weight, height, waist and hip circumference, blood pressure (BP) and heart
rate (HR). BMI and waist-to-hip ratio (WHR) were then calculated. This information was used to
randomly allocate participants into either the treatment or the control group by the chief investigator.
Stratification method of randomization was carried out to ensure that the baseline characteristics
were evenly distributed amongst groups to avoid potential confounding results. The method used to
ensure allocation concealment was sequentially numbered containers. The containers were equal
in weight, similar in appearance and tamper-proof. The principal investigator implemented the
allocation sequence and assigned the participants into their groups. The capsules were opaque and
indistinguishable in appearance, size, texture and smell. The taste of the capsules was identical
provided that they were swallowed whole as instructed. Staff and participants involved in the
intervention process of the trial were blinded to group assignment. The randomization code was
broken only after data analysis was completed. The study was approved by the Human Ethics
Research Committee of Victoria University (VUHERC approval number 14-020). Trial registration:
Australia New Zealand Clinical Trial Registry (ANZCTR): ACTRN12614000305628.
Nutrients 2015, 7, page–page 
and 29 females) were enrolled in the trial (Figure 2). All participants were screened to assess 
eligibility prior to enrolling and informed written consent was obtained. The eligibility criteria 
included: BMI > 25 m² or waist circumference > 94 cm (male) and > 80 cm (female), 20–65 years, 
non-smoker, non-pregnant or lactating, non-type 1 diabetic, no present liver, kidney or heart disease, not 
susceptible to peptic ulcers and not taking any medication for weight loss, hypertension or 
thrombocytosis. Prior to randomization, an initial assessment was conducted to measure 
participant’s weight, height, waist and hip circumference, blood pressure (BP) and heart rate (HR). 
BMI and waist-to-hip ratio (WHR) were then calculated. This information was used to randomly 
allocate participants into either the treatment or the control group by the chief investigator. 
Stratification method of randomization was carried out to ensure that the baseline characteristics 
were evenly distributed amongst groups to avoid potential confounding results. The method used to 
ensure allocation concealment was sequentially numbered containers. The containers were equal in 
eight, similar in appearance and tamper-proof. The principal investigator implemented the 
allocation sequence and assigned the partici a ts i to t eir groups. The capsules were opaque and 
indistinguishable in a pearance, size, text r   ll. The taste of the capsules was identical 
provi ed tha  they were swallowed whole as instr  Staff and partic pants involved in the 
intervention process of the trial were blinded t   ent. The randomization code was 
broken only after d ta analysis was complete . The study was ap roved by the Human Ethics 
Research Co mittee of Victoria University (  a r val number 14-020). Trial registration: 
Australia New Zealand Clinical Trial Registry ( ZCTR): CTR 12614000305628. 
 
Figure 2. Flow chart of study design. 
2.2. Experimental Design 
Olive Life Sciences, India, manufactured and supplied the C. forskohlii extract and the placebo 
capsules for this study. The C. forskohlii extract was obtained from the sun-dried tuberous roots of the 
plant by ethanol grade extraction. The extract was standardized to contain 10% forskolin. Once extracted, 
3 
Figure 2. Flow chart of study design.
9510
Nutrients 2015, 7, 9508–9522
2.2. Experimental Design
Olive Life Sciences, India, manufactured and supplied the C. forskohlii extract and the placebo
capsules for this study. The C. forskohlii extract was obtained from the sun-dried tuberous roots of
the plant by ethanol grade extraction. The extract was standardized to contain 10% forskolin. Once
extracted, the C. forskohlii was then blended with maltodextrin and aerosil, and then pulverized and
packaged into capsules containing 250 mg of C. forskohlii extract. The dosage was determined based
on the previous study by Kamohara and Noparatanawong [24]. Placebo capsules contained 250 mg
of maltodextrin. Participants were instructed to take one capsule twice daily 30 min before main
meals for 12-weeks. Compliance to adhering to this regimen was monitored by providing participants
with a fortnightly capsule calendar to mark of their daily doses and also by counting any remaining
capsules (if any) from their fortnightly supply.
At the beginning of the study (week 1) anthropometric parameters (weight, height, BMI, waist
and hip circumference and WHR), BP, HR and fasting plasma biochemical analysis including ghrelin,
leptin, insulin, triglycerides (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C),
low density lipoprotein cholesterol (LDL-C) and glucose were performed.
In addition, an appetite assessment, food frequency questionnaire (FFQ) [26] and physical
activity questionnaire [27] were also conducted. These investigations were undertaken again at the
conclusion of the study (week 12). Furthermore, dietary intake and physical activity were controlled
during the intervention. Both groups received consistent dietary advice once per fortnight and were
advised to maintain their routine physical activity levels. Dietary intake was monitored through
3-day food diaries obtained at the baseline and weeks 4, 8 and 12 of the study and participation in
physical activity was monitored fortnightly. Participants in both groups were given standard dietary
advice and instructed to follow a hypocaloric diet (deficit of approximately 500 kcal/day of estimated
energy requirements) based on the Adult Weight Management Evidence-Based Nutrition Practice
Guidelines [28]. All anthropometric measurements were taken during fortnightly appointments. At
these visits, participants were also asked to report if any negative side effects were experienced.
2.3. Anthropometry and Physiological Measurements
All anthropometric (weight, height, waist and hip circumference) and physiological
measurements (BP and HR) were performed using standard technique and equipment [29]. BMI
was calculated using the following formula: BMI (kg/m2) = weight/height2. WHR was calculated
using the following formula: WHR = waist circumference (cm)/hip circumference (cm). BP and HR
were measured after the participant had been seated and relaxed for at least five minutes using an
automated digital BP monitor (Omron Healthcare, Kyoto, Japan). All measurements were taken in
duplicate and the mean of the measurements was used as the final result.
2.4. Biochemical Analyses of Metabolic Parameters
At the baseline and at the completion of the 12-week trial, fasting blood samples were collected
for the analysis of plasma leptin, ghrelin, insulin and lipids (TC, HDL-C and TG). Participants were
asked to refrain from exercise and fast for approximately 10 hours (overnight) prior to the blood
collection. Approximately 10 mL of venous blood was drawn from the cubital vein using a winged
needle and BD ethylene diamine tetraacetic acid (EDTA) vacutainer. Immediately after collection,
blood samples were centrifuged for 10 min at 3000 g and 4 ˝C. The plasma was aliquoted into
cryotubes and was stored at ´80 ˝C until analysis. A digital glucometer (Abott Diabetes Care Inc.,
Melbourne, Australia) was used to determine fasting blood glucose concentration.
Plasma concentrations of TG, TC and HDL-C were determined using commercial colorimetric
assay kits (Thermo Fisher Scientific Inc., Middletown, OH, USA) and analyzed with an automated
spectrophotometer in accordance with the manufacturer’s instructions. Plasma LDL-C concentration
was derived using the Friedewald equation [30]: LDL-C = TC ´ HDL-C ´ (TG/2.7) (mmol/L).
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The concentration of plasma leptin and insulin was determined with commercial (Mercodia Inc.
Uppsala, Sweden; Abcam Inc., Cambridge, MA, USA) enzyme linked immunosorbent assay (ELISA)
kits in accordance to the manufacturer’s instructions using an automated spectrophotometer. Total
plasma ghrelin concentration was measured by radioimmunoassay [31] using a commercial kit (Linco
Research, Saint Charles, MI, USA) in accordance to the manufacturer’s instructions. Insulin resistance
was determined using the homeostatic model assessment of insulin resistance (HOMA-IR) [32] with
the following equation: HOMA-IR = fasting insulin (µU/L) ˆ fasting glucose (nmol/L)/22.5.
2.5. Appetite Assessment
Fasting and postprandial appetite was assessed at the baseline and at the end of the intervention
using a previously validated visual analogue scale (VAS) method [33]. Briefly, participants underwent
the VAS following an overnight fast of 10 hours and then the VAS was repeated again after
the ingestion of a standardized buffet-style test breakfast. Appetite sensations were recorded in
the VAS by participants placing a vertical stroke along a 100 mm horizontal line to represent:
how hungry they feel (not hungry-hungry); how full they feel (not full-full); how nauseous they
feel (not nauseous-nauseous); how drowsy they feel (not drowsy-drowsy); how anxious they feel
(not anxious-anxious); how strong their desire to eat is (very weak-very strong); how much food
they think they could eat (none-a large amount). Participants were given thirty minutes to consume
their test breakfast meal. After obtaining the energy content of the test meal, the satiety quotient
(SQ) was then calculated for each appetite sensation (AS) and all time point SQs were averaged
(0–180 min) to evaluate the satiating efficiency of the meal [34] using the following equation:
SQ (mm/ kcal) = (fasting AS ´ post meal AS/energy content of test meal) ˆ 100.
2.6. Dietary Intake
Participants recorded all food and fluid intake for three days (two weekdays and one weekend
day) at baseline and weeks 4, 8 and 12 on dietary recall forms. The dietary intake of energy and
nutrients was then quantified by the researcher using Food Works Professional (Xyris software Pty
Ltd., Highgate Hill, Australia). Additionally, at the baseline and week 12 participants completed a
previously validated [35,36] FFQ (Dietary Questionnaire for Epidemiological Studies (DQES) version
2, Cancer Council, Melbourne, Australia) that assessed their dietary history for energy, macronutrient
and micronutrient intake during the past three months.
2.7. Statistical Analysis
The sample size for the trial (a minimum of 13 in each group) was determined by statistical
power analysis (two tailed t-test at the 0.05 significance level) based on the previous findings of
Henderson, et al. [25] for the power of 90% of expected differences in total energy intake-one of the
major measured outcomes of the trial. All data are presented as mean ˘ standard deviation unless
specified otherwise and were analyzed using SPSS, v19 (IBM, Chicago, IL, USA). Independent t-tests
were performed to compare all baseline data between groups. Mixed model analysis of variance
(ANOVA) was used to analyze the effects of the intervention, time, and the interaction between the
intervention and time with pairwise comparisons (adjusted for multiple comparisons by Bonferroni’s
post-hoc test). Results were considered statistically significant when p < 0.05.
3. Results
Out of 41 enrolled participants 30 completed the trial (control group: n = 15, 12 females and
3 males, experimental group: n = 15, 12 females and 3 males). Eleven participants were lost to follow
up due to time constraints with work and family commitments (Figure 2). There were no significant
differences observed between the two groups at the baseline of the intervention for age, weight, BMI,
waist circumference, hip circumference or WHR (Table 1).
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Table 1. Baseline physical characteristics of the participants at randomization.
Parameter Experimental Group (n = 15) Placebo Group (n = 15) p Value
Age (years) 40.9 ˘ 13.8 41.8 ˘ 14.2 0.9
Body weight (kg) 90.9 ˘ 13.9 93.4 ˘ 21.2 0.9
Body mass index (kg/m²) 31.9 ˘ 4.0 33 ˘ 6.4 0.7
Waist circumference (cm) 105.4 ˘ 11.1 108.5 ˘ 17.8 0.8
Hip circumference (cm) 112.7 ˘ 8.2 113.2 ˘ 12.0 0.8
Waist to hip ratio 0.93 ˘ 0.08 0.96 ˘ 0.1 0.7
Values are expressed as mean ˘ standard deviation (SD), n = number of subjects.
3.1. Anthropometric and Physiological Parameters
Table 2 shows anthropometric measurements and physiological parameters taken at the baseline,
midway and at the end of the intervention. A significant time effect (p < 0.05) was observed in waist
and hip circumference between week 12 and the baseline with mean reductions of 4.5 ˘ 1.7 cm and
3.5 ˘ 1.1 cm recorded in waist circumference in the experimental and placebo groups, respectively;
and 3.4 ˘ 1.1 cm and 3.0 ˘ 1.2 cm reductions in hip circumference in the experimental and placebo
groups, respectively (Table 2). There were no marked differences observed in other anthropometric
or physiological parameters (Table 2).
Table 2. Anthropometric and physiological parameters of participants at baseline, week 6 and week
12 of intervention with C. forskohlii extract (n = 15 in each group).
Parameter Study Group Baseline Week 6 Week 12 p Value
Weight Experimental 89.5 ˘ 13.2 88.6 ˘ 12 88 ˘ 11.4 Group 0.3
(kg) Placebo 92.9 ˘ 21.2 92.2 ˘ 20.5 91.5 ˘ 21 Time 0.3
Interaction 1
BMI Experimental 31.8 ˘ 3.9 30.7 ˘ 3.6 30.4 ˘ 3.4 Group 0.7
(kg/m2) Placebo 32.8 ˘ 6.5 32.6 ˘ 6.4 32.2 ˘ 6.2 Time 0.1
Interaction 1
Waist Experimental 106.9 ˘ 11.7 103.6 ˘ 9.8 102.4 ˘ 11.3 Group 1.0
(cm) Placebo 106.1 ˘ 11.2 103.7 ˘ 11.6 102.6 ˘ 15 * Time 0.02
Interaction 0.7
Hip Experimental 112.3 ˘ 5.9 109.8 ˘ 5 108.9 ˘ 5.4 Group 0.3
(cm) Placebo 115.3 ˘ 13.2 113.8 ˘ 11.9 112.3 ˘ 12.6 * Time 0.01
Interaction 0.6
WHR Experimental 0.95 ˘ 0.09 0.94 ˘ 0.08 0.94 ˘ 0.08 Group 0.3
Placebo 0.92 ˘ 0.08 0.91 ˘ 0.09 0.91 ˘ 0.08 Time 0.3
Interaction 0.8
Systolic BP Experimental 125 ˘ 17 128 ˘ 13 125 ˘ 13 Group 0.3
(mmHg) Placebo 128 ˘ 13 132 ˘ 12 130 ˘ 10 Time 0.4
Interaction 0.8
Diastolic BP Experimental 79 ˘ 8 79 ˘ 9 77 ˘ 9 Group 0.6
(mmHg) Placebo 83 ˘ 8 80 ˘ 8 78 ˘ 10 Time 0.1
Interaction 0.9
Heart Rate Experimental 74 ˘ 13 75 ˘ 12 73 ˘ 13 Group 0.3
(bpm) Placebo 76 ˘ 14 73 ˘ 11 74 ˘ 12 Time 0.1
Interaction 0.6
Values are expressed as mean ˘ SD. * p < 0.05, compared to baseline for each intervention. WHR, waist to hip
ratio; BP, blood pressure.
3.2. Metabolic Parameters
Table 3 shows the results of metabolic parameters at the baseline and end of the intervention.
Supplementation with C. forskohlii extract for 12 weeks significantly reduced (p = 0.001) insulin
concentration compared with the control group (Figure 3). Consistently, there was a significant
difference observed (p = 0.01) in HOMA-IR between the experimental and control group after the
12-week intervention (Figure 4). HDL-C was significantly increased (p = 0.01) at week 12 compared
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to baseline in both groups. No significant differences were observed for blood glucose, TG, TC, HDL
to LDL-C ratio, ghrelin or leptin in either group after the 12-week intervention.
Table 3. Metabolic parameters of participants at baseline and week 12 of intervention with C. forskohlii
extract (n = 15 in each group).
Parameter Baseline Week 12 p Value
Fasting blood glucose (mmol/L) Group 0.9
Experimental 5.3 ˘ 0.5 5.5 ˘ 1.0 Time 0.8
Placebo 5.3 ˘ 1.0 5.5 ˘ 1.4 Interaction 1
Triglycerides (mmol/L) Group 0.2
Experimental 1.2 ˘ 0.5 1.1 ˘ 0.7 Time 0.5
Placebo 1.5 ˘ 1.0 1.4 ˘ 0.6 Interaction 0.8
Total cholesterol (mmol/L) Group 0.9
Experimental 4.1 ˘ 1.2 3.7 ˘ 0.9 Time 0.08
Placebo 4.1 ˘ 1.1 4.5 ˘ 0.7 Interaction 0.9
HDL-C (mmol/L) Group 0.4
Experimental 0.9 ˘ 0.4 1.2 ˘ 0.5 * Time 0.01
Placebo 1.1 ˘ 0.6 1.3 ˘ 0.5 * Interaction 0.7
LDL-C (mmol/L) Group 0.6
Experimental 2.76 ˘ 1.0 2.83 ˘ 1.0 Time 0.5
Placebo 2.5 ˘ 1.7 2.8 ˘ 0.9 Interaction 0.7
HDL:LDL (mmol/L) Group 0.6
Experimental 0.4 ˘ 0.2 0.5 ˘ 0.3 Time 0.7
Placebo 0.5 ˘ 0.1 0.6 ˘ 0.4 Interaction 0.9
Insulin (mU/L) Group 0.8
Experimental 9.6 ˘ 5.7 6.1 ˘ 2.3 Time 0.2
Placebo 6.8 ˘ 3.8 8.5 ˘ 4.1 Interaction 0.001
HOMA-IR Group 1
Experimental 2.3 ˘ 1.5 1.5 ˘ 0.7 Time 0.5
Placebo 1.4 ˘ 0.9 2.1 ˘ 1.4 Interaction 0.01
Ghrelin (pg/mL) Group 0.6
Experimental 622 ˘ 127 647 ˘ 143 Time 0.4
Placebo 643 ˘ 209 686 ˘ 208 Interaction 0.9
Leptin (pg/mL) Group 1
Experimental 33938 ˘ 4117 38783 ˘ 3451 Time 0.8
Placebo 36286 ˘ 5120 32701 ˘ 9609 Interaction 0.5
Values are expressed as mean ˘ SD. * p < 0.05, compared to baseline for each intervention. HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HOMA-IR, Homeostatic
model assessment of insulin resistance
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Placebo 2.5 ± 1.7 2.8 ± 0.9 Interaction 0.7 
HDL:LDL (mmol/L)   Group 0.6 
Experimental 0.4 ± 0.2 0.5 ± 0.3 Time 0.7 
Placebo 0.5 ± 0.1 0.6 ± 0.4 Interaction 0.9 
Insulin (mU/L)   Group 0.8 
Experimental 9.6 ± 5.7 6.1 ± 2.3 Time 0.2 
Placebo 6.8 ± 3.8 8.5 ± 4.1 Interaction 0.001 
HOMA-IR   Group 1 
Experimental 2.3 ± 1.5 1.5 ± 0.7 Time 0.5 
Placebo 1.4 ± 0.9 2.1 ± 1.4 Interaction 0.01 
Ghrelin (pg/mL)   Group 0.6 
Experimental 622 ± 127 647 ± 143 Time 0.4 
Placebo 643 ± 209 686 ± 208 Interaction 0.9 
Leptin (pg/mL)   Group 1 
Experimental 33938 ± 4117 38783 ± 3451 Time 0.8 
Placebo 36286 ± 5120 32701 ± 9609 Interaction 0.5 
Values are expressed as mean ± SD. * p < 0.05, compared to baseline for each intervention. HDL-C, 
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HOMA-IR, 
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Figure 4. Change in insulin resistance over the intervention period. Values are expressed as
mean ˘ SEM. * p < 0.05, compared with placebo group.
3.3. Dietary Intake and Physical Activity
Both food diaries and FFQ were used to assess dietary intake. The results from the food diary
analyses at the baseline and weeks 4, 8 and 12 are shown in Table 4 and that at baseline and
week 12 from FFQ are shown in Table 5. There were significant interactions observed between
the experimental and placebo groups after the 12 week intervention for the intakes of total energy
(p = 0.03), total fat (p = 0.04), saturated fat (p = 0.04), and carbohydrate (p = 0.02) based on the FFQ
(Table 5). The FFQ (Table 5) also revealed a significant between group difference for carbohydrate
intake (p = 0.04) and dietary cholesterol (p = 0.01). There were no significant interactions observed
from the food diary analysis (Table 4), however there was a significant between group difference
for protein intake (p = 0.02) and significant time effects were noted for total energy (p = 0.03),
carbohydrate (p = 0.04), total fat (p = 0.02) and saturated fat (p = 0.01) (Table 4). The IPAQ showed
that there were no significant differences in the amount of reported physical activity participation in
either group at the baseline or after the 12-week intervention.
Table 4. Dietary intake of energy and nutrients obtained from participants’ food diary records at week
1, 4, 8 and 12 (n = 15 in each group).
Nutrient StudyGroup Week 1 Week 4 Week 8 Week 12 p Value
Energy Experimental 8585 ˘ 2705 7717 ˘ 1784 6742 ˘ 1427 6726 ˘ 1306 Group 0.08
(kJ/day) Placebo 9161 ˘ 3316 7923 ˘ 1235 8660 ˘ 2172 8611 ˘ 1888* Time 0.03
Interaction 0.1
Protein Experimental 94 ˘ 31 97 ˘ 19 70 ˘ 12 77 ˘ 10 Group 0.02
(g/day) Placebo 105 ˘ 47 110 ˘ 40 107 ˘ 28 110 ˘ 37 Time 0.1
Interaction 0.1
Carbohydrates Experimental 225 ˘ 62 200 ˘ 57 191 ˘ 53 179 ˘ 36 Group 0.5
(g/day) Placebo 238 ˘ 83 190 ˘ 41 220 ˘ 71 200 ˘ 70 * Time 0.04
Interaction 0.4
Total fat Experimental 79 ˘ 43 66 ˘ 24 53 ˘ 13 * 54 ˘ 14 Group 0.1
(g/day) Placebo 84 ˘ 39 71 ˘ 22 71 ˘ 31 * 81 ˘ 21 * Time 0.02
Interaction 0.2
Saturated fat Experimental 32 ˘ 18 23 ˘ 9 * 20 ˘ 6 * 23 ˘ 9 Group 0.8
(g/day) Placebo 32 ˘ 17 24 ˘ 7 * 23 ˘ 12 * 23 ˘ 7 * Time 0.01
Interaction 0.2
Sodium Experimental 2703 ˘ 824 2518 ˘ 716 2571 ˘ 531 2628 ˘ 820 Group 0.8
(mg/day) Placebo 3072 ˘ 1272 2350 ˘ 532 2504 ˘ 877 2698 ˘ 624 Time 0.06
Interaction 0.4
Alcohol Experimental 7 ˘ 19 0.3 ˘ 1 0.7 ˘ 2 1 ˘ 2 Group 0.8
(g/day) Placebo 7 ˘ 9 2 ˘ 4 2 ˘ 4 0.7 ˘ 2 Time 0.07
Interaction 0.8
Values are expressed as mean ˘ SD. * p < 0.05, compared to baseline for each intervention.
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Table 5. Dietary intake of energy and nutrients reported in FFQ at baseline and week 12.
Parameter Baseline Week 12 p Value
Energy (kJ/day) Group 0.06
Experimental 9012 ˘ 2944 6602 ˘ 1834 Time 1
Placebo 9659 ˘ 2630 8011 ˘ 3339 Interaction 0.03
Protein (g/day) Group 0.06
Experimental 108 ˘ 32 85 ˘ 25 Time 0.8
Placebo 118 ˘ 40 106 ˘ 25 Interaction 0.3
Total fat (g/day) Group 0.1
Experimental 92 ˘ 35 62 ˘ 27 Time 0.6
Placebo 97 ˘ 32 83 ˘ 37 Interaction 0.04
Saturated fat (g/day) Group 0.1
Experimental 36 ˘ 15 24 ˘ 10 Time 0.9
Placebo 39 ˘ 15 31 ˘ 17 Interaction 0.04
Polyunsaturated fat (g/day) Group 0.1
Experimental 14 ˘ 6 10 ˘ 5 Time 0.6
Placebo 15 ˘ 6 13 ˘ 5 Interaction 0.07
Monounsaturated fat (g/day) Group 0.1
Experimental 34 ˘ 13 23 ˘ 11 Time 0.5
Placebo 35 ˘ 11 32 ˘ 14 Interaction 0.08
Cholesterol (mg/day) Group 0.01
Experimental 339 ˘ 115 263 ˘ 83 Time 0.07
Placebo 408 ˘ 147 388 ˘ 177 Interaction 0.9
Carbohydrates (g/day) Group 0.04
Experimental 204 ˘ 77 146 ˘ 29 Time 0.7
Placebo 223 ˘ 67 176 ˘ 45 Interaction 0.02
Fiber (g/day) Group 0.2
Experimental 19 ˘ 6 18 ˘ 4 Time 0.4
Placebo 24 ˘ 8 21 ˘ 7 Interaction 0.2
Alcohol (g/day) Group 0.9
Experimental 12 ˘ 19 7 ˘ 12 Time 0.8
Placebo 11 ˘ 11 6 ˘ 9 Interaction 0.4
Values are expressed as mean ˘ SD.
3.4. Appetite Assessment
There were no significant differences observed in the SQ or the amount of energy consumed
from the test breakfast using the VAS in either group at the baseline or at week 12. Furthermore,
significant differences were not observed in any of the measured appetite sensations after the 12-week
intervention. However, both groups experienced a non-significant decrease in their satiety rating at
week 12.
3.5. Safety and Adverse Events
In general, the C. forskohlii extract and placebo capsule preparations in our study were well
tolerated. There were few adverse events and these were considered mild. Two participants in the
experimental group experienced minor side effects in the first three weeks of the intervention period
(increased bowel motions n =1, loose stools n =1). These symptoms subsided by the fourth week of
the intervention.
4. Discussion
In the present study, supplementation with C. forskohlii extract in conjunction with a hypocaloric
diet did not significantly affect weight loss or other anthropometric measures when compared to the
placebo group. However, a significant time effect was observed in the reduction of waist and hip
circumferences in both groups after the 12 week intervention (Table 2). Therefore, it appears likely
that the reductions in waist and hip circumference occurred due to the dietary advice to follow a
hypocaloric diet. Previous human studies have documented inconsistent results regarding changes
in anthropometry with C. forskohlii supplementation. For instance, Henderson and colleagues [25]
reported no significant changes to body weight or anthropometry, whereas Godard, Johnson and
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Richmond [22] recorded significant reductions in fat mass parallel to significant increases in bone
mass (as determined by dual energy X ray absorptiometry (DXA) but not in total body weight in obese
men after 12 weeks of supplementation with C. forskohlii extract. It is also important to note that the
changes in waist and hip circumference occurred independent of body weight. A possible explanation
for this could be that participants experienced simultaneous gains in bone and muscle mass parallel to
increased fat loss as in the study by Godard, Johnson and Richmond [22]. However, the present study
is limited as body composition was not measured. Methods such as DXA or 3D whole body laser
scans would be useful in future studies to validate this hypothesis. Abdominal obesity is a key feature
of metabolic syndrome as visceral fat is responsible for the secretion of various adipocytokines such
as leptin, interleukin-6 and adiponectin. The secretion of these adipocytokines is altered in metabolic
syndrome and contributes to the chronic inflammatory pathogenesis of the syndrome [37]. Changes
between 1.8 and 4.1 cm in waist circumference are reported to be clinically relevant in individuals
with waist circumferences ranging from 60 to 135 cm [38]. Since waist circumference is a useful
indicator of visceral fat, the significant reduction in waist circumference in both experimental and
placebo groups observed in our study is of potential clinical importance [1,39]. Albeit the change
in waist circumference was achieved over a 12-week period and it is unknown whether the change
would be maintainable over a longer period of time, thus limiting its clinical relevance.
Underreporting of food intake is a common issue in clinical practice and obesity research [40].
It was therefore deemed useful to use two different methods, that is, FFQ and self-reported food
diaries to ascertain food intake throughout the study. The main findings from the present study
was the significant reduction of total energy, total fat, saturated fat, carbohydrate and dietary
cholesterol intakes in the experimental group based on the FFQ which suggests that dietary intake
was significantly affected by C. forskohlii extract supplementation(Table 5). Conversely, the food diary
analyses revealed a significant time effect for total energy, total fat, saturated fat and carbohydrate
intakes which indicates that dietary changes were not significantly influenced by the C. forskohlii
intervention and were instead achieved as a result of the dietary advice to maintain a hypocaloric
diet. The significant time effects observed from the food diary results support the explanation that
the changes in waist and hip circumference were achieved by following hypocaloric diets. The food
diary results of the present study are consistent with that of Henderson, et al. [25] who also reported
a significant time effect in dietary intake. The inconsistencies between the findings of the food diary
records and FFQ are likely to be attributed to the differences in the methods of food intake reporting
used (i.e., the FFQ presents an extensive but not exhaustive list of food items consumed during a given
period of time, whereas the food diary relies on dietary recall from the participants). We recognize
that the present study is limited by inter-individual variability in food intake and the subjective
nature of reporting and interpreting. Furthermore, the validity and reliability of the dietary intake
results would have been strengthened by measuring a biomarker such as urinary minerals or nitrogen
excretion [41]. Although it is not clear how (or if) C. forskohlii supplementation influences dietary fat
intake, emerging studies have shown that low fat taste sensitivity is associated with overweight and
obesity [42,43]. Thus, we hypothesize that by reducing fat tissue (i.e., reducing waist circumference)
in overweight and obese subjects it could have led to improved fat taste sensitivity leading to a
decreased intake of fatty foods as observed in our study.
Ghrelin is a brain-gut peptide that signals hunger and increases food intake in humans [44].
Conversely, leptin is an adipocyte derived hormone that signals satiety in the hypothalamus.
Circulating plasma leptin concentration is proportional to adiposity. In overweight and obesity, leptin
function is thought to be deregulated whereby individuals are desensitized to the hormone and as a
result still experience a heightened desire to eat despite plentiful energy stores [45]. The present study
is the first to assess fasting plasma ghrelin and leptin concentrations following supplementation with
C. forskohlii extract in humans. Previous animal studies have reported that supplementation with
C. forskohlii extract diminished appetite (determined by measured food intake) and reduced weight
gain in rodent models of obesity [46,47]. Despite the significant reductions observed in the
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experimental group for energy and macronutrient intakes, there were no significant changes in fasting
plasma ghrelin or leptin concentrations in either group (Table 3). These findings are consistent with
the appetite and satiety results obtained from the VAS. These results are also in agreement with that
of Henderson, et al. [25] who also reported no significant results from a similar VAS method. Yet the
present study is limited as only single blood samples were collected on each testing day, prior to the
ingestion of the test breakfast meal. To conclusively demonstrate the effect of C. forskohlii extract on
appetite it would be useful to take several blood samples after the ingestion of a test meal to monitor
postprandial changes in ghrelin and to also correlate this data with the responses from the VAS.
Furthermore, the VAS is limited in the sense that it is not completed under normal living conditions
and therefore participants may experience altered appetite sensations compared to what they would
in a free living context [48]. Given that the FFQ results showed that energy intake was significantly
reduced in the experimental group in the present study, analysis of other peptides which regulate
energy balance such as orexin, neuropeptide Y, glucagon-like-peptide-1, and peptide YY would be
useful to further investigate the effects of C. forskohlii supplementation on appetite in humans [49].
Insulin is secreted from the pancreatic beta cells in response to rises in blood glucose
concentration and promotes the cellular uptake of glucose. In the present study we found a
significant decrease in fasting plasma insulin concentration and insulin resistance in the experimental
group. This could be related to the significant decreases in saturated fat and carbohydrate intake
in the experimental group (Table 5). Diets rich in saturated fats have been shown to influence
circulating insulin concentration and insulin sensitivity [10]. Furthermore, the reduced plasma insulin
concentration may be associated with a decreased abdominal fat mass as indicated by the decline
in waist circumference in the experimental group. Insulin is primarily secreted when the body
is in a fed state and has an overall anabolic effect on metabolism, thus causing the body to store
energy [8]. In the pathogenesis of diseases such as T2DM and metabolic syndrome, there is an
increase in hepatic glucose production which results in hyperglycemia and an increased secretion
of insulin leading to hyperinsulinemia. Hyperinsulinemia causes tissues to become desensitized
to insulin and subsequently insulin resistance develops causing chronic hyperglycemia which can
have deleterious effects on the circulatory and renal systems if left untreated [6]. Thus, improving
insulin sensitivity in individuals with, or at risk of developing metabolic syndrome, has an important
clinical implication. In the present study, the significant change in insulin concentration and insulin
resistance was independent of fasting glucose concentration (Table 3). However, the results for fasting
plasma glucose concentration obtained at both the baseline and at week 12 of the study indicate
that both groups were within normal levels (<5.6 mmol/L) regardless of insulin concentration [11].
This implies that insulin sensitivity could have improved after 12 weeks of supplementation in
the experimental group as a lower level of insulin was required to maintain euglycemia. In
comparison, Henderson and colleagues [25], reported no significant changes in fasting insulin or
glucose concentrations for both the placebo and experimental group after 12 weeks supplementation
with C. forskohlii extract.
Low HDL-C (<1.03 mmol/L for females and <1.29 mmol/L for males) is a core feature of the
dyslipidaemia which occurs in the metabolic syndrome [2]. At the baseline of the study, both the
experimental and placebo groups presented with relatively low levels of plasma HDL-C (Table 3).
After the 12 week intervention, both groups showed a significant increase in plasma concentration of
HDL-C (Table 3). The increase in HDL-C concentration may be linked to the reduction of dietary
carbohydrate intake. Previous studies have reported that carbohydrate intake shows an inverse
relationship with circulating HDL-C [50–52]. Furthermore, raised insulin and low HDL-C were
found to be associated with an increased activity of hepatic lipase [53]. It has been shown that
fasting insulin concentration is correlated with the hepatic lipase to lipoprotein lipase ratio, which in
turn is correlated with fasting very-low density lipoprotein cholesterol [53]. The significant increase
in HDL-C concentration is of potential clinical importance as HDL-C has cardio-protective and
anti-inflammatory properties through its role in blocking LDL-C oxidization and thus protects against
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atherosclerosis and coronary heart disease [54,55]. Previous studies have reported that sustained
alterations in dietary cholesterol intake have been associated with modest changes to circulating
levels of TC and LDL-C in individuals with dyslipidaemia. Despite the significant reduction in
dietary cholesterol intake observed in the experimental group, there were no significant changes
observed in the plasma concentrations of LDL-C, TC or TG (Table 3). This might be due to the
relatively short duration of intervention. Further studies of a longer duration and with a larger
sample size would be useful to verify the effect of C. forskohlii extract on blood lipids. Moreover,
circulating lipid levels are more proportionate to the endogenous cholesterol synthesized in the liver
rather than to dietary cholesterol. In metabolic syndrome, the liver synthesizes increased amounts
of very-low density lipoprotein cholesterol and LDL-C and decreased amounts of HDL-C [56]. Thus,
data on hepatic enzyme activity related to cholesterol metabolism in animals supplemented with
C. forskohlii would also be helpful to elucidate the mechanism of C. forskohlii on plasma cholesterol.
Generally C. forskohlii extract supplementation is very well tolerated and is recognized as safe
to use [57]. However there were two reports of adverse events within the experimental group of the
present study which were both related to the gastrointestinal system. This is the first controlled study
to report side effects associated with the supplementation of C. forskohlii extract. It is plausible that the
occurrence of increased bowel motions and loose stools was due to an initial increase in gastric acid
secretion [58] following supplementation with C. forskohlii extract as forskolin has previously been
shown to increase acid formation [59]. The reported gastrointestinal side effects were mild in nature
and did not lead to discontinuation of the intervention. Furthermore, the symptoms subsided within
four weeks of use.
Although the total number of participants satisfied the minimum number required by power
analysis, the sample size was still relatively small and it is unlikely that it was a true representation
of the general overweight and obese adult population, thus limiting the applicability of the results.
For instance, 80% of the participants who completed the study were female. It would be useful for
future studies to restrict participation to a more specific sample population and/or recruit a larger
sample size. Future research directions may focus on measuring specific biomarkers to validate the
reductions in energy intake and implementing DXA scans to evaluate changes in body composition.
Longer term studies may also be warranted in the future to determine whether the favorable changes
are maintainable for an extended period.
5. Conclusions
The major finding of the present study was that supplementation with C. forskohlii extract in
conjunction with a hypocaloric diet significantly improved insulin and insulin resistance and thus
may be useful in the management of metabolic risk factors. Significant increases in HDL-C were
observed in both groups after the 12-week intervention. The intakes of total energy, fat, saturated fat,
carbohydrate and dietary cholesterol were significantly reduced in the experimental group and thus
the present study indicates that supplementation with C. forskohlii extract in conjunction with dietary
advice may be useful for reducing dietary intake. However, further investigation is required as the
dietary results obtained through different methods were inconsistent. Finally, supplementation with
C. forskohlii extract had limited effects on anthropometric measures despite the marked reductions in
dietary intake.
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